Metastatic Uveal Melanoma: Understanding the Journey from Diagnosis to Survivorship

Uveal melanoma is the most common primary eye cancer in adults, arising from melanocytes in the uvea (iris, ciliary body, choroid). When it metastasizes—most often to the liver—it becomes a life-altering diagnosis. While historically grim, emerging therapies and comprehensive care are extending survival and improving quality of life. Here's what patients and families need to know.

Recognizing the Signs

Primary uveal melanoma may be asymptomatic initially. Symptoms prompting evaluation include:

• New or changing pigmented spot on the iris
• Blurred or distorted vision
• Floaters or flashes
• Eye pain or pressure
• Visible bulging of the eye (advanced)

Any new visual change warrants immediate ophthalmology referral.

Diagnosis and Staging

Diagnosis combines dilated fundus exam, ultrasound biomicroscopy, optical coherence tomography (OCT), and often fine-needle aspiration biopsy (for genetic profiling). Staging requires liver-focused imaging (MRI with contrast preferred over CT) and PET-CT. Genetic classification (monosomy 3, BAP1 mutation, gene expression profile) powerfully predicts metastatic risk and guides surveillance intensity.

Treatment Landscape

Primary Eye Treatment

• Plaque brachytherapy (Ru-106, I-125): Most common globe-preserving option.
• Proton beam therapy: Precision for selected tumors.
• Enucleation: For large tumors, glaucoma, or patient preference.
• Local resection: Rare, for anterior tumors.

Metastatic Disease Management

• Immunotherapy: Checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab+nivolumab) show modest response rates (~10–20%) but durable benefit in responders.
• Targeted therapy: TEBENTAFUSP (tebentafusp-tebn)—a bispecific gp100-HLA-A*02:01 TCR fusion protein—is FDA-approved for HLA-A*02:01+ unresectable/metastatic uveal melanoma. First therapy to improve overall survival in randomized trial.
• Liver-directed therapies: Hepatic artery infusion (HAI) chemo, chemoembolization (TACE), radioembolization (TARE/Y-90), percutaneous ablation—for liver-dominant disease.
• Clinical trials: Critical for this orphan disease—novel immunotherapies, TIL therapy, darovasertib (PKC inhibitor), combinations.

Prognosis and What to Expect

Historical 5-year survival for metastatic disease is ~10–15%. Teventafusp and emerging combinations are shifting this. Prognosis depends heavily on metastatic burden, liver involvement, performance status, and genetic class (Class 1 vs. 2). Treatment is typically chronic—cycles of therapy, monitoring, and adaptation.

Managing Side Effects and Quality of Life

Treatment toxicities vary: fatigue, nausea, rash, diarrhea, immune-related adverse events (hepatitis, colitis, endocrinopathies), infusion reactions. Liver-directed therapies carry risks of biliary injury, liver dysfunction. Proactive supportive care (antiemetics, growth factors, dermatology, endocrinology) is essential. Palliative care integration from diagnosis improves symptom control and decision-making.

Living With the Disease: Survivorship Perspective

• Multidisciplinary team: Ocular oncologist, medical oncologist, hepatologist, palliative care, genetics, mental health.
• Surveillance: Liver MRI q3–6mo; PET-CT periodically; ophthalmology for treated eye.
• Support systems: CureOM (Melanoma Research Foundation), Ocular Melanoma Foundation, peer mentors.
• Advance care planning: Goals-of-care conversations early and often.
• Hope grounded in reality: Many patients live years with metastatic disease, maintaining meaningful function and joy.

Metastatic uveal melanoma is a marathon. With expert care, community, and evolving science, the path forward holds more possibility than ever before.